| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.01▼ | 3.02▼ | 3.02▼ | 3.04▼ | 3.07▼ |
| MA10 | 3.02▼ | 3.05▼ | 3.06▼ | 3.03▼ | 3.07▼ |
| MA20 | 3.06▼ | 3.06▼ | 3.05▼ | 3.09▼ | 3.13▼ |
| MA50 | 3.06▼ | 3.03▼ | 3.04▼ | 3.09▼ | 3.06▼ |
| MA100 | 3.04▼ | 3.09▼ | 3.10▼ | 3.11▼ | N/A |
| MA200 | 3.10▼ | 3.09▼ | 3.09▼ | 2.92▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.009▼ | -0.010▼ | -0.007▼ | -0.007▼ | -0.002▼ |
| RSI | 36.054▼ | 41.373▼ | 42.847▼ | 43.763▼ | 48.967▼ |
| STOCH | 6.759▼ | 10.480▼ | 21.474 | 36.668 | 34.354 |
| WILL %R | -95.455▼ | -96.154▼ | -96.154▼ | -82.759▼ | -81.633▼ |
| CCI | -72.026 | -108.103▼ | -121.544▼ | -54.679 | -88.925 |
| MA | $GRCE Price Crossed Below MA(7) | Set Alert |
|
Monday, November 17, 2025 05:14 AM
Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 17/11/25 | 3.06 | 3.08 | 3.00 | 3.00 | 87,441 |
| 14/11/25 | 3.09 | 3.14 | 3.04 | 3.06 | 33,297 |
| 13/11/25 | 3.03 | 3.10 | 3.03 | 3.10 | 47,662 |
| 12/11/25 | 3.02 | 3.055 | 3.02 | 3.03 | 53,912 |
| 11/11/25 | 2.99 | 3.06 | 2.98 | 3.00 | 47,600 |
| 10/11/25 | 3.01 | 3.03 | 2.98 | 2.99 | 40,900 |
| 07/11/25 | 2.99 | 3.039 | 2.95 | 2.99 | 51,137 |
| 06/11/25 | 3.04 | 3.0695 | 2.96 | 3.04 | 33,662 |
| 05/11/25 | 3.07 | 3.105 | 2.977 | 3.00 | 58,350 |
| 04/11/25 | 3.10 | 3.12 | 3.05 | 3.09 | 38,549 |
|
|
||||
|
|
||||
|
|